The agreement provides access for prescribed patients to Lilly's obesity medicines self-pay pricing starting at $149 per month without leaving the platform.
News|Articles|September 1, 2026
Revitalizing recruitment in a lupus rescue study: A collaborative approach by Quest Diagnostics and PatientsLikeMe
Author(s)Quest Diagnostics
Advertisement
Download the case study and learn how Quest Diagnostics and PatientsLikeMe helped accelerate recruitment and enrollment for a struggling study.
This case study is free and can be downloaded and read at your convenience.
Advertisement
Related to this article
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.
Brox.AI’s Hamish Brocklebank on the three approaches to digital twins in pharma — and why only one-to-one clones of real individuals deliver true accuracy.
Advertisement
Advertisement
Trending on PharmExec
1
The US Drug-Pricing Reset: Competing on Net Value
2
Novo Terminates Research Collaboration With Korro Bio
3
Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Rybrevant Faspro
4
Hims & Hers Partners with Eli Lilly to Sell Obesity Medicines
5